March 12, 2026

</aside>

Written by :kaizen: Kaizen Research Team

</aside>

Summary

</aside>

Provided by Kaizen

Kaizen is a premium crypto membership offering expert trade setups, in-depth research, market insights, educational content, and a supportive community to help you win in crypto.

Join now →

</aside>

Kaizen Radar

Introduction

<aside>

This week we're spotlighting two names riding the hottest structural trends in markets right now: the DeFi derivatives revolution and the GLP-1 weight-loss mega-cycle.

Decentralized perpetual exchanges are stealing market share from centralized incumbents at an accelerating pace, with tokenized commodities and real-world assets exploding onto onchain orderbooks.

Meanwhile, the obesity and weight-loss drug market is reshaping healthcare, with landmark pharma partnerships validating telehealth as the distribution layer for the next generation of treatments.

This week's picks give exposure to both of these seismic shifts.

One is the dominant onchain derivatives protocol with a $150 price target from one of crypto's sharpest minds.

The other just secured a game-changing deal with Novo Nordisk that sent its stock soaring 40%+ in a single day.

</aside>

Hyperliquid

<aside>

Ticker: $HYPE

Market: Crypto (L1)

Market Cap: $8.6B Price Change (7d): +15%

Website: https://hyperfoundation.org/

Description:

The leading decentralized perpetual futures exchange built on its own L1, offering lightning-fast execution, deep liquidity, and permissionless tokenized markets for crypto, commodities, and equities via its HIP-3 protocol.

Our Take:

Arthur Hayes (BitMEX co-founder) published his "HYPE Man" thesis setting a $150 price target by August 2026, calling HYPE his largest liquid altcoin bet. Driven by 97% of protocol fees flowing directly into buybacks and burns for holders.
HIP-3 permissionless markets hit $1.2B+ in open interest with crude oil futures (CL-USDC) alone recording $1.99B in 24h volume, this is a 533%+ surge as geopolitical volatility drives traders to Hyperliquid's 24/7 onchain orderbook.
Even in Hayes' most bearish stress test, the model produces a $58 price target (75% upside from current levels), while 30-day annualized revenue sits at $843M and only needs a 4% market share gain to return to $1.4B peak run rate.

https://x.com/CryptoHayes/status/2030972350074908920?s=20

Links: https://x.com/HYPERDailyTK/status/2031212807203774864?s=20

</aside>

Hims & Hers Health

<aside>

Ticker: $HIMS

Market: NYSE

Market Cap: $5.9B Price Change (5d): +85%

Website: https://www.forhims.com/

Description:

A leading telehealth platform providing personalized health and wellness treatments, now the first major direct-to-consumer partner authorized to distribute Novo Nordisk's blockbuster GLP-1 weight-loss drugs Ozempic and Wegovy.

Our Take:

Landmark partnership with Novo Nordisk grants HIMS authorized distribution of branded Ozempic and Wegovy (injections + pills), ending the patent infringement lawsuit and sending the stock up 41% in a single session. Its best day ever, wiping out $546M in short-seller bets.
Wall Street flipped bullish overnight: Needham upgraded to Buy ($30 PT), Barclays raised to $29 (Overweight), Deutsche Bank to $28, BofA doubled its PT to $23, and Citi upgraded from Sell to Neutral ($24). All citing removal of legal overhang and expanded TAM in the booming GLP-1 market.
This deal positions HIMS as the primary telehealth distribution layer for the largest weight-loss drug franchise on Earth, with seamless patient transitions from compounded to branded treatments and a clear path to future partnerships with Eli Lilly and next-gen GLP-1 makers.

Links: https://x.com/himshouse/status/2031392118749426115?s=20

</aside>

<aside>

</aside>